AiPD: Autoinhibited Protein Database

Q9Y385

Gene name	UBE2J1 (NCUBE1, CGI-76, HSPC153, HSPC205)
Protein name	Ubiquitin-conjugating enzyme E2 J1
Names	E2 ubiquitin-conjugating enzyme J1, Non-canonical ubiquitin-conjugating enzyme 1, NCUBE-1, Yeast ubiquitin-conjugating enzyme UBC6 homolog E, HsUBC6e
Species	Homo sapiens (Human)
KEGG Pathway	hsa:51465
EC number	2.3.2.23: Aminoacyltransferases
Protein Class

Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

143-307 (Predicted disordered autoinhibitory region) PR

Target domain
Relief mechanism
Assay	cis-regPred

AID

143-307 (Predicted disordered autoinhibitory region)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

References

Yeon JH et al. (2016) "Systems-wide Identification of cis-Regulatory Elements in Proteins", Cell Systems, 2, 89-100

Autoinhibited structure

Activated structure

1 structures for Q9Y385

Entry ID	Method	Resolution	Chain	Position	Source
AF-Q9Y385-F1	Predicted				AlphaFoldDB

223 variants for Q9Y385

Variant ID(s)	Position	Change	Description	Diseaes Association	Provenance
rs758299881 CA364959907	2	E>D		No	ClinGen ExAC TOPMed gnomAD
CA364959921 rs1400129743	2	E>K		No	ClinGen gnomAD
rs1055012433 CA364959893	3	T>I		No	ClinGen TOPMed gnomAD
rs1055012433 CA142924874	3	T>N		No	ClinGen TOPMed gnomAD
CA3920763 rs750193168	4	R>H		No	ClinGen ExAC gnomAD
CA364959876 rs1164800362	5	Y>C		No	ClinGen gnomAD
rs910733924 CA142924850	5	Y>N		No	ClinGen Ensembl
CA364959868 rs1474370248	6	N>S		No	ClinGen gnomAD
CA364959847 rs1193027961	9	S>N		No	ClinGen gnomAD
TCGA novel	9	S>R	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA142924846 rs867801291	11	A>S		No	ClinGen Ensembl
CA3920745 rs771791752	14	R>C		No	ClinGen ExAC gnomAD
CA364956821 rs1156378232	14	R>H		No	ClinGen TOPMed
rs778835829 CA3920743	16	M>T		No	ClinGen ExAC gnomAD
TCGA novel	18	E>*	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA3920742 rs200104225	19	A>V		No	ClinGen ExAC TOPMed gnomAD
rs981021544 CA142918602	22	L>F		No	ClinGen TOPMed gnomAD
rs777540370 CA3920740	26	T>A		No	ClinGen ExAC gnomAD
rs1582486749 CA364956718	26	T>I		No	ClinGen Ensembl
TCGA novel	27	D>Y	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs770443851 CA142918599	28	H>R		No	ClinGen TOPMed gnomAD
CA3920738 rs751592887	31	A>E		No	ClinGen ExAC TOPMed gnomAD
rs751592887 CA3920739	31	A>V		No	ClinGen ExAC TOPMed gnomAD
rs375490992 CA3920737	32	Q>*		No	ClinGen ESP ExAC gnomAD
rs1179687110 CA364956679	32	Q>R		No	ClinGen gnomAD
rs1374378527 CA364956670	33	P>R		No	ClinGen TOPMed
CA3920736 rs763096948	35	E>K		No	ClinGen ExAC gnomAD
rs1423045933 CA364959805	38	L>V		No	ClinGen TOPMed
CA142955830 rs775747904	39	F>S		No	ClinGen Ensembl
CA364959720 rs1483878465	44	T>M	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
rs750694699 CA3920718	52	D>N	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA TOPMed gnomAD
CA142955779 rs8099 VAR_019689	55	G>V		No	ClinGen UniProt Ensembl dbSNP
CA3920715 rs757663102	56	G>E		No	ClinGen ExAC gnomAD
rs1428776179 CA364959571	57	V>I		No	ClinGen gnomAD
CA364959540 rs754093091	59	H>Q		No	ClinGen ExAC TOPMed gnomAD
rs764665521 CA3920713	60	G>R		No	ClinGen ExAC gnomAD
rs776129230 CA3920711	61	R>Q	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA TOPMed gnomAD
rs761329904 CA3920712	61	R>W		No	ClinGen ExAC gnomAD
rs1164556978 CA364959514	62	I>V		No	ClinGen TOPMed gnomAD
CA364959503 rs1377571198	63	V>I		No	ClinGen TOPMed
CA364959486 rs1416652267	64	L>P		No	ClinGen gnomAD
CA364959429 rs1218265763	69	P>T		No	ClinGen gnomAD
rs1296715391 CA364959351	74	S>R		No	ClinGen TOPMed
TCGA novel	75	I>S	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA364959330 rs1308947714	76	I>S		No	ClinGen TOPMed
rs142719646	79	T>=	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	NCI-TCGA
CA3920707 rs774084923	79	T>M		No	ClinGen ExAC gnomAD
rs779208542 CA3920696	80	A>T		No	ClinGen ExAC gnomAD
rs138380064 CA3920695	81	N>S		No	ClinGen ESP ExAC TOPMed
CA364958805 rs1318560394	83	R>*	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA TOPMed gnomAD
rs754084351 CA3920694	83	R>Q	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA gnomAD
CA364958749 rs1188793869	86	V>L		No	ClinGen TOPMed
rs764609861 CA3920693	87	G>D		No	ClinGen ExAC gnomAD
TCGA novel	89	K>T	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA3920691 rs539906752	94	I>N		No	ClinGen 1000Genomes ExAC gnomAD
rs768098329 CA3920690	97	H>L		No	ClinGen ExAC gnomAD
rs868317393 CA142952411	103	Q>*		No	ClinGen Ensembl
rs759140538 CA3920689	103	Q>P		No	ClinGen ExAC gnomAD
CA364958493 rs773680574	105	S>*		No	ClinGen ExAC TOPMed gnomAD
CA3920688 rs773680574	105	S>L		No	ClinGen ExAC TOPMed gnomAD
CA142952384 rs906394272	106	W>*		No	ClinGen Ensembl
rs1045774434 CA142952374	108	I>V		No	ClinGen gnomAD
rs972323410 CA142952294	110	T>A		No	ClinGen Ensembl
rs749523135 CA3920676	111	A>V		No	ClinGen ExAC gnomAD
rs756579340 CA3920674	115	I>N		No	ClinGen ExAC gnomAD
rs753063341 CA3920673	117	G>R		No	ClinGen ExAC gnomAD
CA3920672 rs768455408	119	M>I		No	ClinGen ExAC
rs867037645 CA142952243	120	P>S		No	ClinGen Ensembl
rs781768933 CA3920670	121	T>A		No	ClinGen ExAC TOPMed gnomAD
CA142952201 rs764695309	121	T>I		No	ClinGen TOPMed
rs1389049746 CA364958340	123	G>R	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA TOPMed
rs1466082564 CA364958314	127	I>V		No	ClinGen TOPMed
rs1440157106 CA364958303	128	G>A		No	ClinGen gnomAD
CA364958296 rs1427687502	129	S>C		No	ClinGen gnomAD
CA3920668 rs752105608	130	L>V		No	ClinGen ExAC gnomAD
rs1304570598 CA364958287	131	D>G		No	ClinGen TOPMed
rs1441790700 CA364958275	133	T>P		No	ClinGen gnomAD
rs140886444 CA3920666	134	P>T		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
rs1320991945 CA364958264	135	E>K		No	ClinGen TOPMed
rs750104620 CA3920665	136	E>K		No	ClinGen ExAC
CA3920663 rs764817698	139	A>V		No	ClinGen ExAC gnomAD
rs776341233 CA3920661	142	K>R		No	ClinGen ExAC TOPMed gnomAD
CA364958206 rs1295636418	143	K>I		No	ClinGen TOPMed
rs1164213338 CA364957832	143	K>N		No	ClinGen TOPMed
CA3920647 rs749873369	146	D>G		No	ClinGen ExAC TOPMed gnomAD
CA364957767 rs1554200775	148	C>G		No	ClinGen Ensembl
rs753474061 CA3920644	151	G>R		No	ClinGen ExAC gnomAD
CA364957662 rs1322437252	154	S>C		No	ClinGen TOPMed
CA3920641 rs775323256	156	M>I		No	ClinGen ExAC gnomAD
CA364957635 rs1340002029	156	M>V		No	ClinGen gnomAD
CA3920639 rs763140036 CA364957587	158	D>E		No	ClinGen ExAC gnomAD
CA364957595 rs1164855346	158	D>N		No	ClinGen gnomAD
CA3920638 rs773363128	159	V>I		No	ClinGen ExAC TOPMed gnomAD
rs769994225 CA3920637	160	L>V		No	ClinGen ExAC gnomAD
rs1197195777 CA364957506	165	S>F		No	ClinGen gnomAD
rs1451329250 CA364957479	167	S>N		No	ClinGen TOPMed gnomAD
rs572279887 CA364957473	167	S>R		No	ClinGen 1000Genomes TOPMed gnomAD
rs554466422 CA3920635	168	D>N		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
CA364957443 rs1208173323	170	S>N		No	ClinGen TOPMed
rs925359773 CA142950255	171	Q>R		No	ClinGen TOPMed gnomAD
rs200248197 CA3920634	177	K>E		No	ClinGen ExAC TOPMed gnomAD
CA3920633 rs367833034	177	K>R		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
rs1562413531 CA364957351	178	E>K		No	ClinGen Ensembl
rs1272781578 CA364957198	181	R>G		No	ClinGen gnomAD
rs570458391 CA3920631	181	R>K		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
TCGA novel	182	Q>E	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA364957176 rs1331410394	182	Q>L		No	ClinGen gnomAD
CA142950206 rs909679519	184	S>R	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA TOPMed
rs376561662 CA3920620	190	N>D		No	ClinGen ESP ExAC gnomAD
CA3920619 rs151000241	190	N>S		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
rs374319811 CA3920618	193	G>E		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
rs765459662 CA3920617	194	K>E		No	ClinGen ExAC gnomAD
CA3920616 rs761957092	194	K>T		No	ClinGen ExAC gnomAD
CA142948947 rs748832646	196	I>T		No	ClinGen Ensembl
rs144602788 CA3920615	196	I>V		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
CA142948942 rs747336938	203	H>N		No	ClinGen ExAC TOPMed gnomAD
CA3920612 rs775989219	203	H>R		No	ClinGen ExAC gnomAD
rs747336938 CA3920613	203	H>Y		No	ClinGen ExAC TOPMed gnomAD
CA3920611 rs772309903	204	S>C		No	ClinGen ExAC TOPMed gnomAD
CA364956518 rs1562411719	206	S>L		No	ClinGen Ensembl
rs371742400 CA3920609	206	S>P		No	ClinGen ESP ExAC TOPMed gnomAD
CA364956507 rs1208880817	208	T>I		No	ClinGen gnomAD
rs748748689 CA3920607	209	D>Y		No	ClinGen ExAC gnomAD
rs1282104574 CA364956492	211	Q>K		No	ClinGen gnomAD
rs777305881 CA3920606	212	D>G		No	ClinGen ExAC gnomAD
rs755726697 CA3920605	213	D>G		No	ClinGen ExAC gnomAD
rs752291099 CA3920604	214	I>T		No	ClinGen ExAC TOPMed gnomAD
rs112892732 CA364956461	215	P>L		No	ClinGen gnomAD
CA142948849 rs112892732	215	P>R	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
rs767405762 CA364956463	215	P>S		No	ClinGen ExAC gnomAD
rs767405762 CA3920603	215	P>T		No	ClinGen ExAC gnomAD
rs567236275 CA3920601	217	T>A		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
CA364956442 rs1223406024	218	F>L		No	ClinGen TOPMed
rs761994024 CA3920600	222	T>K		No	ClinGen ExAC TOPMed gnomAD
CA3920599 rs761994024	222	T>M		No	ClinGen ExAC TOPMed gnomAD
CA3920597 rs764072957	223	A>T		No	ClinGen ExAC TOPMed gnomAD
rs761014012 CA3920596	225	T>I		No	ClinGen ExAC gnomAD
CA364956396 rs776800982 COSM597796	226	S>*	lung [Cosmic]	No	ClinGen cosmic curated ExAC TOPMed gnomAD
rs938339185	226	S>=	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs776800982 CA3920595	226	S>L		No	ClinGen ExAC TOPMed gnomAD
rs199520794	227	Y>=	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	NCI-TCGA
TCGA novel	228	G>E	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs534795677 CA3920576	228	G>R		No	ClinGen 1000Genomes ExAC gnomAD
rs10502 CA142946922	229	L>F		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
CA3920574 rs140328708	229	L>R		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
rs10502 VAR_019690 CA3920575	229	L>V		No	ClinGen UniProt 1000Genomes ESP ExAC TOPMed dbSNP gnomAD
rs372021590 CA3920573	234	A>E		No	ClinGen ESP ExAC TOPMed gnomAD
rs773572450 CA3920571	238	H>Y		No	ClinGen ExAC gnomAD
rs769390748 CA364956028	239	Q>H		No	ClinGen ExAC TOPMed gnomAD
rs1222148920 CA364956024	240	P>A		No	ClinGen TOPMed gnomAD
rs367896104 CA3920569	240	P>R		No	ClinGen ESP ExAC TOPMed gnomAD
rs1222148920 CA364956023	240	P>S		No	ClinGen TOPMed gnomAD
CA3920568 rs781000909	241	T>A		No	ClinGen ExAC
CA3920567 rs768352070	241	T>I		No	ClinGen ExAC gnomAD
rs781000909 CA364956018	241	T>P		No	ClinGen ExAC
TCGA novel	241	T>Y	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA364955986 rs1384148952	244	V>I		No	ClinGen gnomAD
CA364955966 rs1365870879	246	K>E		No	ClinGen TOPMed gnomAD
CA3920563 rs144284760	248	T>I		No	ClinGen ESP ExAC gnomAD
rs148521060 CA142946842	249	S>F		No	ClinGen ESP TOPMed
rs1442245272 CA364955926	250	M>L		No	ClinGen gnomAD
CA3920562 rs778675688	250	M>T		No	ClinGen ExAC gnomAD
CA3920561 rs756240479	252	P>S		No	ClinGen ExAC gnomAD
CA3920560 rs145712020	253	R>*	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ESP ExAC NCI-TCGA TOPMed gnomAD
COSM1082456 rs1172005945 CA364955888	253	R>Q	Variant assessed as Somatic; 0.0 impact. endometrium [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated NCI-TCGA gnomAD
CA3920559 rs767731573	255	R>C	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA TOPMed gnomAD
rs755262556 CA3920558	255	R>H	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA TOPMed gnomAD
COSM1312430 rs202016441 CA3920556	256	R>Q	Variant assessed as Somatic; 0.0 impact. urinary_tract [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated 1000Genomes ESP ExAC NCI-TCGA TOPMed gnomAD
rs374040513 CA3920557	256	R>W		No	ClinGen ESP ExAC TOPMed gnomAD
rs763199768 CA3920555	257	A>T		No	ClinGen ExAC TOPMed gnomAD
rs1051912921 CA142946787	259	Q>H		No	ClinGen Ensembl
CA364955832 rs1197943849	259	Q>K		No	ClinGen gnomAD
rs773803959 CA3920554	259	Q>L		No	ClinGen ExAC TOPMed gnomAD
rs765616172 CA3920553	264	R>S		No	ClinGen ExAC gnomAD
CA3920552 rs761387891	265	L>M		No	ClinGen ExAC gnomAD
CA142946771 rs1025339919	266	S>P		No	ClinGen TOPMed
rs764981521 CA3920549	267	T>A		No	ClinGen ExAC TOPMed gnomAD
CA364955737 rs1300995165	267	T>I		No	ClinGen gnomAD
rs764981521 CA3920550	267	T>P		No	ClinGen ExAC TOPMed gnomAD
rs775250029 CA3920548	268	S>L		No	ClinGen ExAC gnomAD
CA3920545 rs768150991	270	D>G		No	ClinGen ExAC TOPMed gnomAD
rs771932435 CA3920546	270	D>H		No	ClinGen ExAC TOPMed gnomAD
TCGA novel	271	V>A	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA142946719 rs921726874	271	V>I		No	ClinGen Ensembl
CA142946717 rs778923630	272	I>L		No	ClinGen ExAC gnomAD
rs778923630 CA3920544	272	I>V		No	ClinGen ExAC gnomAD
CA3920543 rs757076516	273	Q>R		No	ClinGen ExAC TOPMed gnomAD
CA3920542 rs749220298	274	G>D		No	ClinGen ExAC gnomAD
rs1582477285 CA364955657	275	H>P		No	ClinGen Ensembl
rs138581028 CA3920541	275	H>Y		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
rs149761290 CA3920539	277	P>L		No	ClinGen ESP ExAC TOPMed gnomAD
rs1030806714 CA142946668	279	D>H		No	ClinGen TOPMed
rs766552187 CA3920538	280	N>S		No	ClinGen ExAC TOPMed gnomAD
rs375067208 CA142946629	282	T>A		No	ClinGen Ensembl
rs765625801 CA3920535	282	T>N		No	ClinGen ExAC TOPMed gnomAD
CA364955564 rs1482390343	283	D>V		No	ClinGen gnomAD
CA3920534 rs367798892	284	H>L		No	ClinGen ESP ExAC TOPMed gnomAD
CA3920533 rs367798892	284	H>R		No	ClinGen ESP ExAC TOPMed gnomAD
CA364955488 rs1235299357	291	I>V		No	ClinGen gnomAD
CA364955465 rs1350425806	293	I>F		No	ClinGen TOPMed gnomAD
rs1350425806 CA364955468	293	I>V		No	ClinGen TOPMed gnomAD
rs376109676 CA3920532	295	T>I		No	ClinGen ESP ExAC TOPMed gnomAD
rs1240006135 CA364955422	296	L>F		No	ClinGen gnomAD
rs775303768 CA3920530	299	A>T		No	ClinGen ExAC gnomAD
rs1400879372 CA364955363	300	A>G		No	ClinGen gnomAD
rs1313047141 CA364955354	301	L>F		No	ClinGen gnomAD
rs546702342 CA3920528	302	I>T		No	ClinGen 1000Genomes ExAC gnomAD
CA364955341 rs1436223459	302	I>V		No	ClinGen TOPMed gnomAD
CA3920527 rs147318737	304	R>Q		No	ClinGen ESP ExAC TOPMed gnomAD
rs1470460404 CA364955296	305	R>*		No	ClinGen gnomAD
TCGA novel	305	R>Q	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA3920526 rs200082622	306	I>M		No	ClinGen 1000Genomes ExAC gnomAD
rs1184071899 CA364955246	308	L>V		No	ClinGen gnomAD
rs749275012 CA3920525	309	A>G		No	ClinGen ExAC gnomAD
CA364955235 rs1422060436	309	A>T		No	ClinGen gnomAD
CA3920522 rs759107261	311	E>K	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA TOPMed gnomAD
CA3920523 rs759107261	311	E>Q		No	ClinGen ExAC TOPMed gnomAD
CA364955167 rs1582477168	312	Y>*		No	ClinGen Ensembl
rs758611094 CA3920520	313	I>M		No	ClinGen ExAC gnomAD
rs780341290 CA3920521	313	I>V		No	ClinGen ExAC TOPMed gnomAD
CA364955144 rs1352008696	314	F>L		No	ClinGen TOPMed gnomAD
rs1262946245 CA364955127	315	D>N		No	ClinGen gnomAD
CA364955052 rs1339321565	318	L>S		No	ClinGen TOPMed gnomAD

No associated diseases with Q9Y385

5 regional properties for Q9Y385

Type	Name	Position	InterPro Accession
domain	Dbl homology (DH) domain	235 - 432	IPR000219
domain	Pleckstrin homology domain	472 - 573	IPR001849
domain	Protein kinase C-like, phorbol ester/diacylglycerol-binding domain	39 - 86	IPR002219
domain	ARHGEF2, PH domain	470 - 585	IPR037806
domain	ARHGEF1-like, PH domain	463 - 570	IPR041020

Functions

		Description
EC Number	2.3.2.23	Aminoacyltransferases
Subcellular Localization	Endoplasmic reticulum membrane ; Single-pass type IV membrane protein
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category	No pathway information available

3 GO annotations of cellular component

Name	Definition
endoplasmic reticulum membrane	The lipid bilayer surrounding the endoplasmic reticulum.
integral component of membrane	The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane.
nucleus	A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.

3 GO annotations of molecular function

Name	Definition
ATP binding	Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.
ubiquitin conjugating enzyme activity	Isoenergetic transfer of ubiquitin from one protein to another via the reaction X-ubiquitin + Y -> Y-ubiquitin + X, where both the X-ubiquitin and Y-ubiquitin linkages are thioester bonds between the C-terminal glycine of ubiquitin and a sulfhydryl side group of a cysteine residue.
ubiquitin protein ligase binding	Binding to a ubiquitin protein ligase enzyme, any of the E3 proteins.

7 GO annotations of biological process

Name	Definition
negative regulation of retrograde protein transport, ER to cytosol	Any process that stops, prevents or reduces the frequency, rate or extent of retrograde protein transport, ER to cytosol.
protein N-linked glycosylation via asparagine	The glycosylation of protein via the N4 atom of peptidyl-asparagine forming N4-glycosyl-L-asparagine; the most common form is N-acetylglucosaminyl asparagine; N-acetylgalactosaminyl asparagine and N4 glucosyl asparagine also occur. This modification typically occurs in extracellular peptides with an N-X-(ST) motif. Partial modification has been observed to occur with cysteine, rather than serine or threonine, in the third position; secondary structure features are important, and proline in the second or fourth positions inhibits modification.
protein polyubiquitination	Addition of multiple ubiquitin groups to a protein, forming a ubiquitin chain.
regulation of macrophage cytokine production	Any process that modulates the rate, frequency or extent of macrophage cytokine production. Macrophage cytokine production is the appearance of a chemokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
regulation of tumor necrosis factor production	Any process that modulates the frequency, rate or extent of tumor necrosis factor production.
spermatid development	The process whose specific outcome is the progression of a spermatid over time, from its formation to the mature structure.
ubiquitin-dependent ERAD pathway	The series of steps necessary to target endoplasmic reticulum (ER)-resident proteins for degradation by the cytoplasmic proteasome. Begins with recognition of the ER-resident protein, includes retrotranslocation (dislocation) of the protein from the ER to the cytosol, protein ubiquitination necessary for correct substrate transfer, transport of the protein to the proteasome, and ends with degradation of the protein by the cytoplasmic proteasome.

12 homologous proteins in AiPD

UniProt AC	Gene Name	Protein Name	Species	Evidence Code
Q16763	UBE2S	Ubiquitin-conjugating enzyme E2 S	Homo sapiens (Human)	EV
Q9NPD8	UBE2T	Ubiquitin-conjugating enzyme E2 T	Homo sapiens (Human)	PR
Q96LR5	UBE2E2	Ubiquitin-conjugating enzyme E2 E2	Homo sapiens (Human)	PR
Q969T4	UBE2E3	Ubiquitin-conjugating enzyme E2 E3	Homo sapiens (Human)	PR
Q9H8T0	AKTIP	AKT-interacting protein	Homo sapiens (Human)	PR
P61086	UBE2K	Ubiquitin-conjugating enzyme E2 K	Homo sapiens (Human)	PR
O00762	UBE2C	Ubiquitin-conjugating enzyme E2 C	Homo sapiens (Human)	PR
O14933	UBE2L6	Ubiquitin/ISG15-conjugating enzyme E2 L6	Homo sapiens (Human)	PR
Q7Z7E8	UBE2Q1	Ubiquitin-conjugating enzyme E2 Q1	Homo sapiens (Human)	PR
A1L167	UBE2QL1	Ubiquitin-conjugating enzyme E2Q-like protein 1	Homo sapiens (Human)	PR
Q9JJZ4	Ube2j1	Ubiquitin-conjugating enzyme E2 J1	Mus musculus (Mouse)	PR
Q9LSP7	UBC32	Ubiquitin-conjugating enzyme E2 32	Arabidopsis thaliana (Mouse-ear cress)	PR

10	20	30	40	50	60
METRYNLKSP	AVKRLMKEAA	ELKDPTDHYH	AQPLEDNLFE	WHFTVRGPPD	SDFDGGVYHG
70	80	90	100	110	120
RIVLPPEYPM	KPPSIILLTA	NGRFEVGKKI	CLSISGHHPE	TWQPSWSIRT	ALLAIIGFMP
130	140	150	160	170	180
TKGEGAIGSL	DYTPEERRAL	AKKSQDFCCE	GCGSAMKDVL	LPLKSGSDSS	QADQEAKELA
190	200	210	220	230	240
RQISFKAEVN	SSGKTISESD	LNHSFSLTDL	QDDIPTTFQG	ATASTSYGLQ	NSSAASFHQP
250	260	270	280	290	300
TQPVAKNTSM	SPRQRRAQQQ	SQRRLSTSPD	VIQGHQPRDN	HTDHGGSAVL	IVILTLALAA
310
LIFRRIYLAN	EYIFDFEL